Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

被引：0
|
作者：
Berenson, James R.
Cohen, Alexa
Spektor, Tanya M.
Lashkari, Ashkan
Mackintosh, Roy
Bessudo, Alberto
Jhangiani, Haresh
Gabrail, Nashat
Nakhoul, Ibrahim
Kubba, Samir
Neidhart, Jeffrey D.
Tina, Maluso
Swift, Regina
Vescio, Robert
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3106
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
    Moustafa, Muhamad Alhaj
    Parrondo, Ricardo
    Abdulazeez, Mays F.
    Roy, Vivek
    Sher, Taimur
    Alegria, Victoria R.
    Warsame, Rahma M.
    Fonseca, Rafael
    Rasheed, Ahsan
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Kapoor, Prashant
    Buadi, Francis K.
    Dingli, David
    Hayman, Suzanne R.
    Reeder, Craig B.
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    ANTI-CANCER DRUGS, 2024, 35 (01) : 63 - 69
  • [22] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David S. Siegel
    Gary J. Schiller
    Christy Samaras
    Michael Sebag
    Jesus Berdeja
    Siddhartha Ganguly
    Jeffrey Matous
    Kevin Song
    Christopher S. Seet
    Giampaolo Talamo
    Mirelis Acosta-Rivera
    Michael Bar
    Donald Quick
    Bertrand Anz
    Gustavo Fonseca
    Donna Reece
    William E. Pierceall
    Weiyuan Chung
    Faiza Zafar
    Amit Agarwal
    Nizar J. Bahlis
    Leukemia, 2020, 34 : 3286 - 3297
  • [23] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Pierceall, William E.
    Chung, Weiyuan
    Zafar, Faiza
    Agarwal, Amit
    Bahlis, Nizar J.
    LEUKEMIA, 2020, 34 (12) : 3286 - 3297
  • [24] Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
    Ulrike Klein
    Kai Neben
    Thomas Hielscher
    Christiane Heiß
    Anthony D. Ho
    Hartmut Goldschmidt
    Annals of Hematology, 2011, 90 : 429 - 439
  • [25] Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment
    Klein, Ulrike
    Neben, Kai
    Hielscher, Thomas
    Heiss, Christiane
    Ho, Anthony D.
    Goldschmidt, Hartmut
    ANNALS OF HEMATOLOGY, 2011, 90 (04) : 429 - 439
  • [26] EFFICACY AND SAFETY OF LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL LIFE EXPERIENCE
    Soyer, N.
    Patir, P.
    Uysal, A.
    Duran, M.
    Unal, H. D.
    Tombuloglu, M.
    Sahin, F.
    Vural, F.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S36 - S36
  • [27] Erratum: Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
    D S Siegel
    P Richardson
    M Dimopoulos
    P Moreau
    C Mitsiades
    D Weber
    J Houp
    C Gause
    S Vuocolo
    J Eid
    T Graef
    K C Anderson
    Blood Cancer Journal, 2014, 4 : e202 - e202
  • [28] Spotlight on Lenalidomide in Relapsed or Refractory Multiple Myeloma
    Lesley J. Scott
    Katherine A. Lyseng-Williamson
    BioDrugs, 2011, 25 : 333 - 337
  • [29] Lenalidomide for the treatment of relapsed or refractory multiple myeloma
    Weber, D. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 22 - 24
  • [30] Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide
    Mariz, Jose Mario
    Esteves, Graca Vasconcelos
    CURRENT OPINION IN ONCOLOGY, 2012, 24 : S3 - S12
12345